CBIOCrescent Biopharma, Inc.
$14.10+25% 1Y
$14.10
$8.9452 weeks$26.98
CBIO in its own filings
CBIO's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
205
Events found in the filings · across 674 filings · the record starts in 2013
- Hard flags
- 1
Hard flags
- Most recent filing
- Jul 30, 2026
Most recent filing · Form 10-Q
- Record starts
- Sep 19, 2013
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountantpast_3y
- 2025-06-18
- Delisting notice / listing-rule failure4 occurrences
- 2024-12-26
- SEC comment-letter activity24 occurrences
- 2026-01-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 15, 2026On July 14, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and …Other event · Form 8-K
- Dec 4, 2025Strategic Transaction with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. On December 2, 2025, Crescent Biopharma Operating Company, LLC (“Crescent OpCo”), the wholly owned subsidiary of Crescent Biopharma, Inc., a Cayman Islands exempted company (together with its subsidiaries, “Crescent” or the “Company”) …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…